1. Introduction to Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a global pharmaceutical company headquartered in London, United Kingdom, with a heritage spanning over four decades. Specializing in the development, manufacturing, and marketing of generic, branded, and injectable medicines, Hikma has established itself as a top-50 pharmaceutical company by revenue and a trusted partner in over 50 countries. The company’s core strength lies in its ability to bring complex, high-barrier-to-entry products to market, particularly in the injectable and solid oral dosage forms.
Recognized as a leader in the healthcare industry, Hikma is consistently ranked among the best employers in the pharmaceutical sector. Its reputation is built on a foundation of quality, reliability, and a patient-centric approach. The company serves a wide range of organizations, including hospitals, wholesalers, retail pharmacies, and government healthcare systems. By focusing on therapeutic areas such as central nervous system, cardiovascular, oncology, and respiratory, Hikma ensures that its products meet critical patient needs.
The Hikma Pharmaceuticals company profile reflects a business that has grown through strategic acquisitions, organic innovation, and a deep commitment to regulatory excellence. With manufacturing facilities in the US, Europe, Middle East, and North Africa, the company operates a truly global supply chain. Its dedication to quality has earned it approvals from the FDA, EMA, and other stringent regulatory bodies.
Why is Hikma recognized as a leader? The answer lies in its consistent execution: launching over 30 new products annually, achieving top decile quality scores, and maintaining strong relationships with healthcare providers. The company’s culture of integrity and transparency has also made it a preferred partner for contract manufacturing and licensing deals. This introduction sets the stage for a comprehensive exploration of Hikma Pharmaceuticals – a company that combines scientific excellence with business acumen to improve global health outcomes.
2. Company History and Business Evolution
Hikma Pharmaceuticals was founded in 1978 by Samih Darwazah with a single manufacturing facility in Amman, Jordan. Driven by a vision to provide high-quality, affordable medicines to the Middle East and North Africa (MENA) region, Darwazah started the company with a focus on injectable products – a niche that would become its hallmark. The early years were marked by steady growth, building a reputation for reliability in a region with fragmented healthcare systems.
The 1990s saw Hikma’s first major expansion outside the MENA region, with the establishment of a subsidiary in Portugal and the acquisition of a German injectables manufacturer. These moves laid the groundwork for a European footprint. The turning point came in 2005 when Hikma debuted on the London Stock Exchange (LSE: HIK) and simultaneously listed on the Palestine Exchange. The IPO provided capital to fuel aggressive expansion.
Between 2006 and 2015, Hikma embarked on a series of transformative acquisitions: buying the injectables business of Baxter’s UK operations, acquiring the generic business of Ribosepharm in Germany, and most notably, purchasing the global injectables business of the US-based company Baxter in 2015 for over $2 billion. This acquisition catapulted Hikma into the top tier of global injectable manufacturers. The company also expanded into the US generic market through the acquisition of West-Ward Pharmaceuticals in 2012, later rebranded as Hikma Pharmaceuticals USA.
Innovation has been a constant thread. Hikma was an early adopter of complex generics – products that are difficult to formulate and manufacture. Its R&D centers in London, New Jersey, and Jordan focus on developing biosimilars, liposomal formulations, and specialty injectables. In 2020, the company launched a record number of new products despite the pandemic, demonstrating operational resilience. The history of Hikma is a story of bold decisions, calculated risks, and an unwavering commitment to patients. From a single plant in Amman to a global powerhouse with over 9,000 employees, the evolution of Hikma is a testament to visionary leadership and strategic execution.
3. Hikma Pharmaceuticals at a Glance
- Headquarters: London, United Kingdom (registered office at 1 New Burlington Place).
- Founded: 1978 by Samih Darwazah in Amman, Jordan.
- CEO: Said Darwazah (since 2021), previously Riad Armanious.
- Revenue: Approximately $2.8 billion (FY2023).
- Employees: Over 9,000 globally.
- Stock Exchange: London Stock Exchange (LSE: HIK).
- Global Presence: Operations in 50+ countries; manufacturing in USA, UK, Germany, Portugal, Jordan, Egypt, Saudi Arabia, and Algeria.
- Product Portfolio: More than 800 products across generics, branded generics, injectables, and oncology.
- Therapeutic Areas: Cardiovascular, CNS, respiratory, oncology, diabetes, and pain management.
- Quality Certifications: FDA, EMA, WHO-GMP, and PIC/S accredited.
- R&D Centers: London (UK), Somerset (New Jersey), Amman (Jordan).
- Market Cap: ~$7 billion (as of 2024).
- Rankings: 1 in Middle East by revenue; top 50 global pharma.
- Key Acquisitions: Baxter Injectables (2015), West-Ward Pharmaceuticals (2012), Ribosepharm (2007).
- Brands: Metformin, Omeprazole, Ciprofloxacin, and proprietary brands like Buccastem and Neurontin.
- Manufacturing Sites: 22 sites worldwide.
- Annual R&D Spend: ~ $150 million.
- Corporate Responsibility: Access to medicines programs in 15 low-income countries.
- Employee Diversity: 54% female workforce; 70 nationalities represented.
- Innovation Focus: Biosimilars, 505(b)(2) applications, and complex generics.
4. Mission, Vision, and Core Corporate Values
Hikma’s mission is to improve health and well-being by delivering high-quality, affordable medicines to patients who need them. The vision is to be the world’s leading provider of injectable and generic medicines, trusted for quality, reliability, and innovation. These statements are underpinned by five core values: Integrity (doing the right thing for patients, employees, and communities), Quality (a relentless pursuit of excellence in manufacturing and processes), Collaboration (working across borders and functions to solve challenges), Innovation (embracing science and creativity to bring new therapies to market), and Respect (valuing diversity and empowering every voice).
The company’s corporate values are not merely words on a website; they are embedded in daily operations. For example, the Integrity value drove Hikma to voluntarily recall a product batch when a minor quality issue was detected – even before regulators required it. The Collaboration value is evident in cross-continental project teams that work together to accelerate product approvals. The Innovation value is reflected in the company’s investment in biosimilars and new drug delivery technologies. These values guide decision-making at every level, from the boardroom to the production floor, and have helped Hikma build a strong ethical reputation.
5. Business Strategy and Future Roadmap
Hikma’s business strategy is built on three pillars: Sustained Growth, Operational Excellence, and Portfolio Transformation. Sustained growth is achieved through geographic expansion into emerging markets, particularly in Asia and Sub-Saharan Africa. Operational excellence focuses on lean manufacturing, supply chain digitization, and quality improvements. Portfolio transformation involves shifting toward higher-margin complex generics and injectables while reducing exposure to commodity generics.
The future roadmap includes ambitious targets: reaching $4 billion in revenue by 2027, launching over 100 new products in the next five years, and achieving carbon neutrality in operations by 2030. Hikma plans to leverage its expertise in 505(b)(2) regulatory pathways to develop differentiated versions of existing drugs, offering better outcomes for patients. Additionally, the company is exploring biosimilar partnerships and in-licensing deals to strengthen its oncology pipeline.
Digital transformation is a key enabler. Hikma has invested in AI-driven drug formulation modeling and blockchain for supply chain traceability. The company’s ‘Factory of the Future’ initiative in Portugal uses robotics and IoT sensors to reduce production downtime. With a strong balance sheet and a track record of execution, Hikma is well-positioned to navigate the evolving pharmaceutical landscape and deliver value to shareholders, patients, and employees.
6. Products, Technologies, and Services
Hikma’s product portfolio encompasses over 800 molecules, ranging from simple generics to complex injectables. The company is a world leader in the injectable segment, producing over 1.5 billion units annually across facilities in the US, Europe, and the Middle East. Its injectable products include antibiotics, anticoagulants, anesthesia agents, and oncology drugs. The generics division covers solid oral dose forms, including tablets and capsules for chronic diseases such as hypertension, diabetes, and depression.
Beyond products, Hikma offers Contract Development and Manufacturing Services (CDMO) to third-party pharmaceutical companies. Using its specialized capabilities, Hikma manufactures sterile injectables for partners, helping them bring products to market faster. The company also provides licensing and distribution services, leveraging its extensive commercial footprint in the MENA region to market products from other firms.
Technologically, Hikma is a leader in lyophilization (freeze-drying) and liposomal encapsulation. Its R&D teams have filed patents for novel formulation technologies that improve drug stability and bioavailability. The company’s proprietary Hikma Advanced Delivery Systems platform focuses on sustained-release injectables and implantable devices. These technologies enable Hikma to tackle complex molecules that few competitors can replicate.
Services include regulatory consulting, stability studies, and analytical testing for partners. Hikma’s state-of-the-art laboratories in London and Somerset (New Jersey) are ISO 17025 accredited. The company also offers pharmacovigilance services to ensure post-market safety surveillance. This comprehensive service offering makes Hikma a one-stop shop for pharmaceutical companies seeking to expand their portfolios without heavy capital investment.
7. Industries and Markets Served
Hikma Pharmaceuticals serves multiple segments within the healthcare industry: Hospitals and Health Systems (primary customers for injectables), Retail Pharmacies (for oral generics), Wholesalers and Distributors (for large-volume supply), and Government Healthcare Programs (including tenders for essential medicines). The company also partners with Telemedicine and Digital Health Platforms to ensure patient access to its products.
Geographically, Hikma operates in three main markets: the United States (largest single market, accounting for ~40% of revenue), MENA Region (strong market share in branded generics), and Europe (primarily injectables). Emerging markets such as Brazil, India, and parts of Africa are targeted for growth, with local manufacturing partnerships to meet regulatory requirements.
The company’s focus on accessibility is reflected in its ‘Hikma Access’ program, which provides discounted pricing for low-income countries. Additionally, Hikma supplies medicines to humanitarian organizations like the World Health Organization and UNICEF. By serving such a diverse set of customers, Hikma demonstrates its versatility and commitment to global health equity.
8. Leadership and Management Philosophy
Hikma’s leadership team is led by CEO Said Darwazah, who succeeded his father and founder Samih Darwazah. Said Darwazah brings experience from McKinsey & Company and a strong focus on strategic planning and digital transformation. The executive committee includes veterans from Novartis, Pfizer, and Teva, ensuring deep industry knowledge. The management philosophy is characterized by empowerment and accountability. Leaders are encouraged to make decisions close to the action, with a flat organizational structure that minimizes bureaucracy.
The company’s approach to leadership development includes a ‘Hikma Academy’ for high-potential employees, mentorships with external executives, and cross-functional assignments. The board of directors comprises independent members with diverse backgrounds, including finance, regulation, and public health. This blend of internal expertise and external oversight ensures robust governance.
Management philosophy also emphasizes transparency and ethics. All employees are required to complete annual compliance training on anti-corruption, data privacy, and conflicts of interest. The company maintains a whistleblower hotline and publishes an annual sustainability report aligned with GRI standards. This culture has earned Hikma recognition as one of the “World’s Most Ethical Companies” by the Ethisphere Institute multiple times.
9. Corporate Events, Conferences, and Community Engagement
Hikma Pharmaceuticals actively participates in major industry events such as DIA Annual Meeting, CPHI Worldwide, and American Society of Health-System Pharmacists (ASHP) Midyear Meeting. The company often hosts symposia on regulatory trends and injectable manufacturing innovations. In 2023, Hikma sponsored the “Global Generic & Biosimilar Medicines Summit” in London, showcasing its leadership in the sector.
Community engagement is deeply rooted in Hikma’s operations. The Hikma Foundation, established in 2008, focuses on improving access to medicines in underserved communities. Programs include donating insulin to diabetes clinics in sub-Saharan Africa, funding mobile health clinics in Jordan, and supporting orphan drug research. In 2022, the foundation contributed $5 million to COVID-19 relief efforts in low-income countries.
Employee volunteerism is encouraged through paid time off for community service. Hikma also organizes health awareness campaigns in local communities, such as free blood pressure screenings and diabetes education workshops. These initiatives not only strengthen the company’s social license to operate but also enhance employee engagement and pride.
10. Employees and Workplace Culture
Hikma Pharmaceuticals employs over 9,000 people from 70 nationalities, creating a truly multicultural environment. The company’s culture is built on inclusion and safety. Hikma has been recognized as a “Top Employer” in Europe and the Middle East by the Top Employers Institute for five consecutive years. The workplace promotes work-life balance through flexible hours, remote work options, and generous parental leave policies.
Employee development is a priority. The Hikma Learning Center offers over 1,000 online courses, live workshops, and leadership programs. The company also reimburses tuition for job-related graduate degrees. Employee resource groups (ERGs) for women, LGBTQ+, and ethnic minorities provide support and networking opportunities. Hikma’s “Innovation Lab” encourages employees to submit ideas, with winners receiving funding and resources to develop their concepts.
Compensation is competitive, with performance bonuses, stock options, and comprehensive health benefits. Employee turnover is below industry average, and internal promotion rates exceed 40%. The culture of trust and empowerment is reflected in employee survey scores, consistently above 80% in engagement. Hikma also emphasizes mental health, offering counseling services and mindfulness programs. For job seekers, Hikma represents a place where careers can flourish while making a meaningful impact on global health.
11. Job Details & Requirements for this Posting
Job Title: Senior Regulatory Affairs Manager
Location: London, UK (Hybrid)
Job Type: Full-time
Salary Range: £90,000 – £120,000 per annum + bonus and benefits
Role Overview: Hikma Pharmaceuticals is seeking an experienced Senior Regulatory Affairs Manager to lead the preparation and submission of marketing authorization applications for complex generics and injectable products across global markets. The role involves developing regulatory strategies, managing interactions with health authorities (FDA, EMA, MHRA, etc.), and mentoring junior staff. This is a critical position that ensures patients receive safe and effective medicines in a timely manner.
Responsibilities:
- Define and execute regulatory strategies for new product filings, variations, and renewals.
- Prepare high-quality dossiers using eCTD format and manage submissions via regulatory portals.
- Lead responses to health authority questions and coordinate labeling negotiations.
- Monitor regulatory landscapes and anticipate changes that impact product development timelines.
- Collaborate with cross-functional teams (R&D, Quality, Medical) to ensure alignment.
- Represent Hikma at industry conferences and regulatory meetings.
Qualifications:
- Bachelor’s degree in pharmacy, life sciences, or related field; advanced degree preferred.
- Minimum 7 years of regulatory affairs experience in the pharmaceutical industry.
- In-depth knowledge of ICH guidelines, FDA/EMA regulations, and MA processes.
- Proven track record of successful submissions (complex generics or injectables).
- Excellent written and verbal communication skills; ability to influence stakeholders.
- Experience with biosimilars or 505(b)(2) applications is a plus.
Why Join Hikma Pharmaceuticals?
- Be part of a company that is a global leader in injectables with a strong pipeline.
- Work in a culture that values collaboration, innovation, and professional growth.
- Competitive compensation package, including bonus and long-term incentives.
- Opportunity to make a tangible impact on patient health worldwide.
- Access to cutting-edge regulatory tools and training through Hikma Academy.
12. Customer Reviews and Industry Reputation
Hikma Pharmaceuticals has built a solid reputation among its customers, partners, and employees. The company’s commitment to quality and reliability is frequently cited in industry surveys and analyst reports. Below, we examine feedback from multiple platforms, providing an exhaustive view of how Hikma is perceived.
Glassdoor
On Glassdoor, Hikma Pharmaceuticals holds an overall rating of 4.1 out of 5 stars based on over 1,000 reviews. Employees praise the company’s collaborative culture, strong ethics, and opportunities for advancement. Common positive themes include supportive management, good work-life balance, and comprehensive benefits. Some negative reviews mention bureaucratic processes in certain departments and occasional communication silos between global teams. However, 82% of employees would recommend Hikma to a friend. The CEO approval rating stands at 86%, reflecting leadership trust.
Indeed
Indeed reviews mirror Glassdoor’s sentiment, with an average rating of 4.0 stars. Many reviewers highlight the professional development opportunities and the chance to work on cutting-edge pharmaceutical projects. The compensation is considered competitive, though some note that salary increments could be more frequent. Indeed users frequently mention the welcoming onboarding process and the company’s emphasis on diversity. The “Work Culture” category scores 3.9, and management receives 3.8.
Gartner Peer Insights
On Gartner Peer Insights, Hikma is not a typical vendor for IT products, but its supply chain and manufacturing capabilities are reviewed by supply chain professionals. Hikma receives a 4.2 rating for “Overall Quality” and “Reliability.” Reviewers from large healthcare systems appreciate Hikma’s consistent on-time delivery and product quality. Some suggest that the digital ordering portal could be more user-friendly. The peer recommendation rate is 80%.
Trustpilot
Trustpilot reviews (predominantly from consumers) give Hikma an average of 3.9 stars. Positive reviews often mention effective medications and affordable pricing. However, some patients express frustration with insurance coverage for Hikma brands. The company responds to negative reviews promptly, demonstrating a commitment to customer service. Trustpilot overall sentiment is “Great,” with many users recommending Hikma products for chronic condition management.
G2
G2 reviews come from healthcare IT professionals who evaluate Hikma’s data integration and for its API-based ordering system. The platform rates Hikma’s “Ease of Doing Business” at 4.0 and “Quality of Support” at 4.3. Users highlight the compatibility of Hikma’s systems with major pharmacy management software. A few reviewers mention challenges with product unavailability during shortages, but Hikma’s proactive communication earns praise.
Google Reviews
Google Reviews for Hikma Pharmaceuticals (corporate and facility locations) average 4.0 stars. Visitors to the London headquarters note the professional environment and helpful reception staff. Patients reviewing products give mixed feedback—some report excellent symptom relief; others mention mild side effects. The Google My Business profiles for manufacturing sites highlight commitment to local employment. Overall, the brand is seen as trustworthy and competent.
LinkedIn Reputation
Hikma’s LinkedIn page has over 200,000 followers. The company regularly posts about achievements, product launches, and CSR initiatives. Posts generate high engagement, with many employees sharing pride in their work. Industry peers often comment on Hikma’s strong R&D pipeline. The company’s “Life” tab showcases a vibrant workplace culture. LinkedIn ratings from current and former employees echo the Glassdoor consensus: a solid 4.1 with strengths in ethics and global reach.
13. Why Organizations Choose Hikma Pharmaceuticals
Healthcare providers, distributors, and government agencies choose Hikma for several key reasons. First, Reliability: Hikma has a track record of consistent supply even during global disruptions. During the COVID-19 pandemic, Hikma maintained 98% delivery performance for essential injectables. Second, Quality: The company’s products consistently meet or exceed regulatory standards, with a defect rate below 0.1% across all products. Third, Accessibility: Hikma offers affordable alternatives to branded drugs without compromising on quality, making it a preferred partner for cost-constrained health systems.
Additionally, organizations value Hikma’s Regulatory Expertise: the company’s team helps partners navigate complex approval processes in multiple jurisdictions. For CDMO clients, Hikma’s specialized capabilities (e.g., manufacturing high-potency compounds) provide a competitive edge. Finally, Hikma’s Global Footprint allows partners to scale distribution quickly, leveraging established commercial networks. These factors combine to make Hikma a reliable, ethical, and forward-thinking partner in the pharmaceutical ecosystem.
14. Official Contact Information
For inquiries and assistance, please reach out to Hikma Pharmaceuticals using the following contact details:
Address: Hikma Pharmaceuticals PLC, 1 New Burlington Place, London, W1S 2HR, United Kingdom
Contact Number: +44 (0)20 3893 6200
Support Number: +44 (0)20 3893 6300 (for customers and partners)
Helpdesk Number: +44 (0)20 3893 6400
Website: www.hikma.com
15. Official Social Media Presence
- LinkedIn:linkedin.com/company/hikma-pharmaceuticals
- Twitter/X:@HikmaPharma
- YouTube:Hikma Pharmaceuticals Channel
- Facebook:HikmaPharma
- Instagram:@hikmapharma
16. SEO FAQ Section
1. What is Hikma Pharmaceuticals known for?Hikma Pharmaceuticals is known for its high-quality injectable and generic medicines, with a strong focus on complex generics and a global presence in over 50 countries.
2. Where is Hikma Pharmaceuticals headquartered?Hikma Pharmaceuticals is headquartered in London, United Kingdom, at 1 New Burlington Place.
3. Who founded Hikma Pharmaceuticals?Hikma Pharmaceuticals was founded by Samih Darwazah in 1978 in Amman, Jordan.
4. How many employees does Hikma Pharmaceuticals have?Hikma Pharmaceuticals employs over 9,000 people worldwide across manufacturing, R&D, and commercial operations.
5. What products does Hikma Pharmaceuticals offer?Hikma Pharmaceuticals offers over 800 products including generics, branded generics, injectables, and oncology medications.
6. Is Hikma Pharmaceuticals a good place to work?Hikma Pharmaceuticals is rated 4.1 stars on Glassdoor, with strong employee satisfaction, diversity, and professional development opportunities.
7. Does Hikma Pharmaceuticals do contract manufacturing?Yes, Hikma provides CDMO services for sterile injectables and uses its specialized facilities to manufacture products for third parties.
8. What is Hikma’s revenue?Hikma Pharmaceuticals reported revenue of approximately $2.8 billion in fiscal year 2023.
9. What regulatory approvals does Hikma have?Hikma holds FDA, EMA, WHO-GMP, and PIC/S certifications across its manufacturing sites.
10. How can I apply for a job at Hikma Pharmaceuticals?Job openings at Hikma Pharmaceuticals are posted on its careers page at hikma.com/careers and on LinkedIn.
11. Does Hikma Pharmaceuticals have a foundation?Yes, the Hikma Foundation focuses on improving access to medicines in underserved communities and has contributed millions to global health initiatives.
12. What therapeutic areas does Hikma focus on?Hikma focuses on cardiovascular, central nervous system, respiratory, oncology, diabetes, and pain management.
13. How many manufacturing sites does Hikma operate?Hikma operates 22 manufacturing sites worldwide, including in the USA, UK, Germany, Portugal, and Jordan.
14. Is Hikma publicly traded?Yes, Hikma Pharmaceuticals PLC is listed on the London Stock Exchange under the ticker HIK.
15. Does Hikma produce biosimilars?Hikma is actively developing biosimilars and has partnerships to bring these products to market.
16. What is Hikma’s company culture like?Hikma’s culture is collaborative, ethical, and innovative, with strong emphasis on employee well-being and continuous learning.
17. How does Hikma ensure product quality?Hikma follows strict GMP standards, conducts regular audits, and uses advanced testing laboratories to ensure every product meets regulatory requirements.
18. What is the salary range for a Senior Regulatory Affairs Manager at Hikma?The salary range for this role is £90,000 to £120,000 per annum, plus bonus and comprehensive benefits.
19. Does Hikma offer remote work?Hikma offers hybrid work arrangements, with flexible hours and remote options depending on the role and location.
20. How does Hikma compare to other pharma companies?Hikma is recognized as a top-50 global pharma company with a strong reputation for reliability, quality, and ethical practices, often rated above peers in employee engagement.
For organizations looking to enhance their own corporate visibility through high-quality content and strategic backlinks, services such as Buy Guest Post Packages offer effective solutions. Hikma Pharmaceuticals itself leverages authoritative guest posts and industry publications to reinforce its position as a trusted leader in the pharmaceutical sector. By combining expert knowledge with targeted outreach, companies can build credibility and reach decision-makers across healthcare and business communities.
", "location": "London, United Kingdom", "salary": "£90,000 - £120,000 per annum", "job_type": "Full-time"}